Literature DB >> 10566644

Prospectively measured levels of serum follicle-stimulating hormone, estradiol, and the dimeric inhibins during the menopausal transition in a population-based cohort of women.

H G Burger1, E C Dudley, J L Hopper, N Groome, J R Guthrie, A Green, L Dennerstein.   

Abstract

The aims of this study were: 1) to describe, in relation to the date of final menses, the average hormone levels of women in the years before and after this date and to determine the extent to which these average levels were dependent on age and body mass index (BMI); and 2) to determine the degree of tracking in residual hormone levels [i.e., the extent to which individuals above (below) the mean for their age or time relative to final menstrual period (FMP) and BMI remain above (below) the mean as time progresses]. Serial levels of serum FSH, circulating estradiol (E2), and the dimeric inhibins (INH) A and B were measured annually in 150 women who experienced a natural menopause during 6 years of follow-up. Means of the log-transformed hormonal levels were analyzed as a double-logistic function of time relative to FMP, as well as age and BMI and correlations between repeated hormonal levels, were measured. Mean FSH levels started to increase from about 2 years before the FMP, increased most rapidly about 10 months before the FMP, and had virtually plateaued by 2 years after the FMP. FSH levels were, on average, 3% greater for each year of age and 2% lower for each kg/m2 of BMI. After adjusting for time relative to the FMP, logFSH showed modest tracking. Age-adjusted values of logFSH were moderately correlated across time, and much of this tracking was explained by the actual timing of a woman's FMP. Mean E2 levels started to decrease about 2 years before the FMP, decreased most rapidly around the time of the FMP, and had virtually plateaued by 2 years after the FMP. E2 levels were lower, on average, by about 9% per year of age, and residual values showed weak tracking. Levels of both INHA and INHB decreased, on average, in the years before the FMP and were undetectable (INHA, < 10 pg/mL; INHB, < 25 pg/mL) in the majority of women by the time of the FMP and in almost all women by 4 years post-FMP. Significant negative correlations between log serum FSH and log E2 (r = -0.73) and log INHA (r = -0.41) and log INHB (r = -0.36) were observed. It is concluded that substantial changes in reproductive hormone levels occur within 1-2 yr on each side of the FMP, that falling concentrations of E2 and the INH contribute to the rising concentrations of FSH, and that there is no single reliable hormonal marker of menopausal status for an individual woman.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10566644     DOI: 10.1210/jcem.84.11.6158

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  75 in total

1.  Do changes in sex steroid hormones precede or follow increases in body weight during the menopause transition? Results from the Study of Women's Health Across the Nation.

Authors:  Rachel P Wildman; Ping G Tepper; Sybil Crawford; Joel S Finkelstein; Kim Sutton-Tyrrell; Rebecca C Thurston; Nanette Santoro; Barbara Sternfeld; Gail A Greendale
Journal:  J Clin Endocrinol Metab       Date:  2012-06-21       Impact factor: 5.958

2.  Anxiety as a risk factor for menopausal hot flashes: evidence from the Penn Ovarian Aging cohort.

Authors:  Ellen W Freeman; Mary D Sammel
Journal:  Menopause       Date:  2016-09       Impact factor: 2.953

Review 3.  Ovarian aging and the perimenopausal transition: the paradox of endogenous ovarian hyperstimulation.

Authors:  Jerilynn C Prior
Journal:  Endocrine       Date:  2005-04       Impact factor: 3.633

4.  Burden of pelvis fracture: a population-based study of incidence, hospitalisation and mortality.

Authors:  D Prieto-Alhambra; F F Avilés; A Judge; T Van Staa; X Nogués; N K Arden; A Díez-Pérez; C Cooper; M K Javaid
Journal:  Osteoporos Int       Date:  2012-02-04       Impact factor: 4.507

5.  Lifelong estradiol exposure and risk of depressive symptoms during the transition to menopause and postmenopause.

Authors:  Wendy K Marsh; Joyce T Bromberger; Sybil L Crawford; Katherine Leung; Howard M Kravitz; John F Randolph; Hadine Joffe; Claudio N Soares
Journal:  Menopause       Date:  2017-12       Impact factor: 2.953

6.  Ultrafine Angelica gigas powder normalizes ovarian hormone levels and has antiosteoporosis properties in ovariectomized rats: particle size effect.

Authors:  Kyeong-Ok Choi; Inae Lee; Sae-Yeol-Rim Paik; Dong Eun Kim; Jung Dae Lim; Wie-Soo Kang; Sanghoon Ko
Journal:  J Med Food       Date:  2012-10       Impact factor: 2.786

7.  Age at natural menopause and risk of ischemic stroke: the Framingham heart study.

Authors:  Lynda D Lisabeth; Alexa S Beiser; Devin L Brown; Joanne M Murabito; Margaret Kelly-Hayes; Philip A Wolf
Journal:  Stroke       Date:  2009-02-20       Impact factor: 7.914

8.  Female cancer survivors exposed to alkylating-agent chemotherapy have unique reproductive hormone profiles.

Authors:  Lauren Johnson; Mary D Sammel; Allison Schanne; Lara Lechtenberg; Maureen Prewitt; Clarisa Gracia
Journal:  Fertil Steril       Date:  2016-09-22       Impact factor: 7.329

9.  "Anti-Mullerian Hormone: Marker for Ovarian Response in Controlled Ovarian Stimulation for IVF Patients": A First Pilot Study in the Indian Population.

Authors:  Neeta Singh; Ekta Malik; Ayan Banerjee; Kunzang Chosdol; V Sreenivas; Suneeta Mittal
Journal:  J Obstet Gynaecol India       Date:  2013-02-22

10.  Sex steroid hormone profiles are related to sleep measures from polysomnography and the Pittsburgh Sleep Quality Index.

Authors:  Mary Fran Sowers; Huiyong Zheng; Howard M Kravitz; Karen Matthews; Joyce T Bromberger; Ellen B Gold; Jane Owens; Flavia Consens; Martica Hall
Journal:  Sleep       Date:  2008-10       Impact factor: 5.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.